Myalgic encephalomyelitis/chronic fatigue syndrome affects at least 2 million people in the United States. Despite its prevalence, there’s no laboratory test for the disease, and its diagnosis is based on symptoms like exhaustion, unrefreshing sleep, and light sensitivity. For patients with this debilitating condition, getting a diagnosis is often a long and expensive process. Now, a long-awaited biomarker-based test for the mysterious disease could be on the horizon.
Abbasi J. Biomarker Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. JAMA. 2019;322(2):107. doi:10.1001/jama.2019.8890
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: